RNA cancer vaccines

A cancer vaccine and vaccine technology, applied in the field of RNA cancer vaccines, can solve problems such as inhibition, activation, and insertional mutagenesis

Pending Publication Date: 2019-11-26
MODERNATX INC
View PDF132 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the case of this technique, potential problems arise with DNA integration into the genome of the vaccine, including the possibility of insertional mutagenesis, which can lead to the activation of oncogenes or the suppression of tumor suppressor genes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RNA cancer vaccines
  • RNA cancer vaccines
  • RNA cancer vaccines

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0678] Formulations of the vaccine compositions described herein can be prepared by any method known or later developed in the art of pharmacology. In general, such methods of preparation comprise the steps of bringing into association the active ingredient (e.g., mRNA polynucleotide) with excipients and / or one or more other auxiliary ingredients, followed by, if necessary and / or desirable, Divide, shape and / or package the product into desired single or multi-dose units.

[0679] Cancer RNA vaccines can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) allow sustained or delayed release (e.g., from a depot formulation); (4) Alter biodistribution (eg, targeting specific tissues or cell types); (5) Increase in vivo translation of the encoded protein; and / or (6) Alter the in vivo release profile of the encoded protein (antigen). In addition to conventional excipients such as any and all solvents, dispersion media, diluents...

Embodiment 1

[1567] Example 1. Production of polynucleotides

[1568] According to the present disclosure, the manufacture of polynucleotides and parts or regions thereof can be achieved using the methods taught in the International Application WO2014 / 152027 entitled "Manufacturing Methods for Production of RNA Transcripts", the contents of which are incorporated by reference Incorporated into this article as a whole.

[1569] Purification methods may include those taught in International Applications WO2014 / 152030 and WO2014 / 152031, each of which is incorporated herein by reference in its entirety.

[1570] Methods of detection and characterization of polynucleotides can be performed as taught in WO2014 / 144039, which is hereby incorporated by reference in its entirety.

[1571] Characterization of polynucleotides of the present disclosure can be accomplished using a program selected from the group consisting of polynucleotide mapping, reverse transcriptase sequencing, charge distributi...

Embodiment 2

[1572] Embodiment 2 chimeric polynucleotide synthesis

[1573] introduction

[1574] According to the present disclosure, two regions or portions of a chimeric polynucleotide can be joined or linked using triphosphate chemistry.

[1575] According to this method, a first region or portion of 100 nucleotides or less is chemically synthesized with a 5' monophosphate and a terminal 3' desOH or blocked OH. If the region is longer than 80 nucleotides, it can be synthesized as two strands for ligation.

[1576] If the first region or portion is synthesized using in vitro transcription (IVT) as a non-position-modified region or portion, then conversion to the 5' monophosphate and subsequent capping of the 3' end may follow.

[1577] The monophosphate protecting group can be selected from any one known in the art.

[1578] The second region or portion of the chimeric polynucleotide can be synthesized using chemical synthesis or IVT methods. IVT methods can include RNA polymerase...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal Tcell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.

Description

[0001] related application [0002] This application is made pursuant to Title 35, United States Code, Section 119(e) of U.S. Provisional Application Serial No. 62 / 453,444, filed February 1, 2017, entitled "RNACANCER VACCINES," filed February 1, 2017, entitled INTEREST OF THE FILING DATES OF U.S. PROVISIONAL APPLICATIONS Serial No. 62 / 453,465 FOR "IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENEMUTATION PEPTIDES" AND THE FILING DATES OF U.S. PROVISIONAL APPLICATIONS SERIAL NO. , each of which is incorporated herein by reference in its entirety. [0003] Background of the invention [0004] Recent theories of cancer evolution have focused on three steps, including stress-induced genome instability, population diversity or heterogeneity, and genome-mediated macroevolution. The theory explains most of the known molecular mechanisms that contribute to cancer, but no single major mechanism exists in most clinical cases. However, common mechanisms suggest...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7088A61P35/00A61K39/00A61K39/39A61K31/7105
CPCA61K39/39A61K31/7105A61P35/00A61K2039/505A61K2039/53A61K2039/55516A61K2039/55555A61K39/001164A61K45/06A61K31/7115A61K39/0011A61K2039/585A61K2039/54A61K2039/545A61K31/7088A61K35/00
Inventor 尼古拉斯·瓦利安特特德·阿什伯恩克里斯滕·霍普森
Owner MODERNATX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap